Floatz logo

Alpelisib

ER-positive Breast Cancer

University of MiamiSmall moleculePhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the ER-positive Breast Cancer cohort.

Asset / SponsorPhaseRating
Everolimus
UNC Lineberger Comprehensive Cancer Center
Phase 4BBB
Ribociclib
National Cancer Institute (NCI)
Phase 3BB
Elacestrant
Kristina A. Fanucci
Phase 3BB
Trastuzumab Deruxtecan
Danish Breast Cancer Cooperative Group
Phase 3BB
DEXAMETHASONE
MedSIR
Phase 3B

View all 10 →

Same molecule, other indications

Alpelisib is also rated in:

triple-negative breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
HER2 positive breast carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
Sickle Cell AnemiaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →